AJP - Heart Calcium Transients and Cell-Sarcomere
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol 289: H1013-H1019, 2005. First published April 15, 2005; doi:10.1152/ajpheart.00068.2005
0363-6135/05 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
289/3/H1013    most recent
00068.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (30)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Igase, M.
Right arrow Articles by Ferrario, C. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Igase, M.
Right arrow Articles by Ferrario, C. M.

Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1–7) expression in the aorta of spontaneously hypertensive rats

Michiya Igase, William B. Strawn, Patricia E. Gallagher, Randolph L. Geary, and Carlos M. Ferrario

Hypertension and Vascular Disease Center and Department of General Surgery, Wake Forest University School of Medicine, Winston-Salem, North Carolina

Submitted 24 January 2005 ; accepted in final form 12 April 2005

When increased in vascular tissues, angiotensin-converting enzyme 2 (ACE2), a carboxypeptidase that hydrolyzes angiotensin II to angiotensin-(1–7), may augment the growth inhibitory and vasodilatory effects of the heptapeptide. We investigated the regulation of ACE2 and angiotensin-(1–7) expression in aortas and carotid arteries of 12-wk-old male spontaneously hypertensive rats (SHR) by determining the effect of sustained angiotensin type 1 (AT1) receptor blockade with olmesartan (10 mg·kg–1·day–1, n = 13) compared with those that received atenolol (30 mg·kg–1·day–1, n = 13), hydralazine (10 mg·kg–1·day–1, n = 13), or vehicle (n = 21). Systolic blood pressures were ~30% lower (P < 0.05) in rats treated for 2 wk with olmesartan compared with vehicle-treated rats. Both atenolol and hydralazine produced similar decreases in systolic blood pressure. ACE2 mRNA in the thoracic aorta of olmesartan-treated rats (n = 8) was fivefold greater (P < 0.05) than that in vehicle-treated rats (n = 16), whereas atenolol (n = 8) or hydralazine (n = 8) had no effect. Immunostaining intensities in rats treated with olmesartan (n = 5) were also associated with increased (P < 0.05) ACE2 and angiotensin-(1–7) in thoracic aorta media compared with vehicle-treated rats. In contrast, immunostaining intensities for both ACE2 and angiotensin-(1–7) were not different from vehicle (n = 5) in carotid arteries of SHR medicated with either atenolol (n = 5) or hydralazine (n = 5). A comparison of vessel wall dimensions showed that olmesartan selectively reduced the thoracic aorta media-to-lumen ratio (P < 0.05) and media thickness (P < 0.05) without an effect on carotid artery morphometry. Compared with vehicle-treated SHR, vascular hypertrophy determined from media and lumen measurements was not changed in SHR given either atenolol or hydralazine. These data represent the first report of ACE2 and angiotensin-(1–7) expression in the aorta and carotid arteries of SHR. Increased ACE2 and angiotensin-(1–7) in association with altered dimensions of the thoracic aorta but not carotid arteries in response to olmesartan treatment provides evidence that this pathway is regulated by AT1 receptors and may be important in mediating the pressure-independent vascular remodeling effects of angiotensin peptides.

angiotensin-converting enzyme 2; angiotensin type 1 receptor; vascular remodeling



Address for reprint requests and other correspondence: C. M. Ferrario, Hypertension and Vascular Disease Center, Wake Forest Univ. School of Medicine, Medical Center Blvd., Winston-Salem, NC 27157 (E-mail: cferrari{at}wfubmc.edu)




This article has been cited by other articles:


Home page
Cardiovasc ResHome page
P. M. Cummins
A new addition to the renin-angiotensin peptide family: proAngiotensin-12 (PA12)
Cardiovasc Res, April 1, 2009; 82(1): 7 - 8.
[Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
M. J. Soler, M. Ye, J. Wysocki, J. William, J. Lloveras, and D. Batlle
Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan
Am J Physiol Renal Physiol, February 1, 2009; 296(2): F398 - F405.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
P. E. Gallagher, C. M. Ferrario, and E. A. Tallant
MAP kinase/phosphatase pathway mediates the regulation of ACE2 by angiotensin peptides
Am J Physiol Cell Physiol, November 1, 2008; 295(5): C1169 - C1174.
[Abstract] [Full Text] [PDF]


Home page
Mol. Interv.Home page
D. I. Diz
Future Directions in Cardiovascular Pharmacology: Examples from the Renin-Angiotensin System
Mol. Interv., October 1, 2008; 8(5): 222 - 225.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
M. Gupte, C. M. Boustany-Kari, K. Bharadwaj, S. Police, S. Thatcher, M. C. Gong, V. L. English, and L. A. Cassis
ACE2 is expressed in mouse adipocytes and regulated by a high-fat diet
Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2008; 295(3): R781 - R788.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. Epelman, W.H. W. Tang, S. Y. Chen, F. Van Lente, G. S. Francis, and S. Sen
Detection of Soluble Angiotensin-Converting Enzyme 2 in Heart Failure: Insights Into the Endogenous Counter-Regulatory Pathway of the Renin-Angiotensin-Aldosterone System
J. Am. Coll. Cardiol., August 26, 2008; 52(9): 750 - 754.
[Abstract] [Full Text] [PDF]


Home page
Ther Adv Cardiovasc DisHome page
C. Schindler
ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist`s perspective after publication of the results of ONTARGET
Therapeutic Advances in Cardiovascular Disease, August 1, 2008; 2(4): 233 - 248.
[Abstract] [PDF]


Home page
Exp PhysiolHome page
I. Hamming, H. van Goor, A. J. Turner, C. A. Rushworth, A. A. Michaud, P. Corvol, and G. Navis
Differential regulation of renal angiotensin-converting enzyme (ACE) and ACE2 during ACE inhibition and dietary sodium restriction in healthy rats
Exp Physiol, May 1, 2008; 93(5): 631 - 638.
[Abstract] [Full Text] [PDF]


Home page
Exp PhysiolHome page
J. L. Guy, D. W. Lambert, A. J. Turner, and K. E. Porter
Functional angiotensin-converting enzyme 2 is expressed in human cardiac myofibroblasts
Exp Physiol, May 1, 2008; 93(5): 579 - 588.
[Abstract] [Full Text] [PDF]


Home page
Exp PhysiolHome page
Z. Lin, Y. Chen, W. Zhang, A. F. Chen, S. Lin, and M. Morris
RNA interference shows interactions between mouse brainstem angiotensin AT1 receptors and angiotensin-converting enzyme 2
Exp Physiol, May 1, 2008; 93(5): 676 - 684.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
V. Koka, X. R. Huang, A. C.K. Chung, W. Wang, L. D. Truong, and H. Y. Lan
Angiotensin II Up-Regulates Angiotensin I-Converting Enzyme (ACE), but Down-Regulates ACE2 via the AT1-ERK/p38 MAP Kinase Pathway
Am. J. Pathol., May 1, 2008; 172(5): 1174 - 1183.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
Y. Feng, X. Yue, H. Xia, S. M. Bindom, P. J. Hickman, C. M. Filipeanu, G. Wu, and E. Lazartigues
Angiotensin-Converting Enzyme 2 Overexpression in the Subfornical Organ Prevents the Angiotensin II-Mediated Pressor and Drinking Responses and Is Associated With Angiotensin II Type 1 Receptor Downregulation
Circ. Res., March 28, 2008; 102(6): 729 - 736.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
S. Heeneman, J. C. Sluimer, and M. J.A.P. Daemen
Angiotensin-Converting Enzyme and Vascular Remodeling
Circ. Res., August 31, 2007; 101(5): 441 - 454.
[Abstract] [Full Text] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
W. C De Mello, C. M Ferrario, and J. A Jessup
Beneficial versus harmful effects of Angiotensin (1-7) on impulse propagation and cardiac arrhythmias in the failing heart
Journal of Renin-Angiotensin-Aldosterone System, June 1, 2007; 8(2): 74 - 80.
[Abstract] [PDF]


Home page
Cardiovasc ResHome page
S. Keidar, M. Kaplan, and A. Gamliel-Lazarovich
ACE2 of the heart: From angiotensin I to angiotensin (1-7)
Cardiovasc Res, February 1, 2007; 73(3): 463 - 469.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
I. F. Benter, M. H. M. Yousif, C. Cojocel, M. Al-Maghrebi, and D. I. Diz
Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction
Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H666 - H672.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
C. M. Ferrario
Angiotensin-Converting Enzyme 2 and Angiotensin-(1-7): An Evolving Story in Cardiovascular Regulation
Hypertension, March 1, 2006; 47(3): 515 - 521.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
I. F. Benter, M. H. M. Yousif, J. T. Anim, C. Cojocel, and D. I. Diz
Angiotensin-(1-7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME
Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H684 - H691.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
C. M. Ferrario, A. J. Trask, and J. A. Jessup
Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function
Am J Physiol Heart Circ Physiol, December 1, 2005; 289(6): H2281 - H2290.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
A. P. V. Dantas and K. Sandberg
Regulation of ACE2 and ANG-(1-7) in the aorta: new insights into the renin-angiotensin system in the control of vascular function
Am J Physiol Heart Circ Physiol, September 1, 2005; 289(3): H980 - H981.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2005 by the American Physiological Society.